Idiotypic and anti-idiotypic antibodies against polycyclic aromatic hydrocarbon in human blood serum are new biomarkers of lung cancer

Abstract

Evaluation of epidemiologic risk factor in relation to lung cancer invoked by polycyclic aromatic hydrocarbons has been inconsistent. To address this issue, we conducted a prospective evaluation of new biomarkers for lung cancer classified according levels of idiotypic and anti-idiotypic antibodies against polycyclic aromatic hydrocarbons in human blood serum. The blood serums of 557 lung cancer patients and 227 healthy donors were analysis of these antibodies by ELISA. Collected data were regrouped and analyzed by gender, smoking, and age as predictors of risk lung cancer factors. Also, the data of lung cancer patients were additionally analyzed by stages and types of lung cancer, surgery, and chemotherapy. It was suggested to use ratio of idiotypic and anti-idiotypic antibodies rather than distinguish level each of them separately. The ratio of levels in healthy people was 3.32 times higher than in lung cancer patients. This approach gave more precisely results and great prognostic value. The logistic regression model (AUC = 0.9) and neural networks (AUC = 0.95) were built to compare lung cancer patients and healthy donors by predictors. The ELISA data of 49 people random sampled from the originally ELISA data and ELISA data of 52 coal miners as a group of lung cancer risk were confirmed logistic regression model. So, suggested idiotypic and anti-idiotypic antibodies against polycyclic aromatic hydrocarbons were not only shown difference between healthy donors and lung cancer patients also elicited group of lung cancer risk among healthy people.

Detection of antibodies against benzo[a]pyrene in blood sera of lung cancer patients by ELISA using human recombinant idiotypic and anti-idiotypic antibodies

“…In the system using a panel of 7 auto-Abs against: p53, CAGE, NY-ESO-1, GBU4-5, SOX2, MAGE A4 and Hu-D, the sensitivity was 47%, the specificity was 90%, and AUC was 0.9. Also, the new method was comparable to previously published one where Bp-BSA and mouse scFv against Bp used for detection of endogenous Ab1 and Ab2 levels against Bp in sera, which gave AUC = 0.9 at logistic regression model [16].…”

“…The proposed method as well as the previously published one [16] shows an increase in serum Abs levels in LC patients compared to healthy people. The small difference between the data presented and those previously published can be explained by the different spectrum of serum Abs that interact with the antigens absorbed onto the immunological plate or by the difference in the number of tested Interestingly, despite these minor differences, the ratio of Ab2 to Ab1 is very similar for both methods.…”

“…The ratio of anti-Bp Ab2/Ab1 in mouse serum after immunization coincided with the ratio of anti-Bp Ab2/Ab1 in sera of lung cancer (LC) patients. In our previous paper, we suggested to use the levels of Ab1 and Ab2 against PAHs as well as Ab2/Ab1 ratios in serum as immunological markers of LC for identifying LC risk groups in healthy population [16]. However, these previous studies were performed using heterogeneous enzyme-linked immunosorbent assay (ELISA).…”

“…However, these previous studies were performed using heterogeneous enzyme-linked immunosorbent assay (ELISA). The Bp-bovine serum albumin (BSA) conjugate was used for detection of endogenous Ab1 against PAHs in sera [16]. The rabbit polyclonal Abs against Bp-BSA or mouse single-chain variable fragment (scFv) against Bp were used for detection of endogenous Ab2 against PAHs in sera [15 , 16].…”

Applying an Exposome-wide Association Study (ExWAS) Approach to Latino Cancer Disparities

“…Biomarkers of Exposure These markers highlight the significance of various exposure pathways and cancer risk; they allow measurement of carcinogens of interest in the body from an accessible biological matrix such as blood, urine, normal, and tumor tissues. For individuals who are either occupationally or dietarily exposed to polycyclic aromatic hydrocarbons (PAHs) (risks for lung cancer [32]) or aflatoxin B (risks for liver cancer [15]) either individually or in mixtures, metabolites of these chemicals in serum or urine serve as markers of exposure.…”